Adakveo (crizanlizumab-tmca) from Novartis is FDA indicated for reducing the number of vaso-occlusive crises in people aged 16 years and older with sickle cell disease. Novartis describes it as “the first and only once-monthly medication to reduce the number of pain crises in sickle cell disease.” The drug works by inhibiting selectin, a group of carbohydrate-binding transmembrane molecules…